NCT07291180RecruitingNot Applicable
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
Yale University1 site in 1 country20 target enrollmentStarted: February 17, 2026Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Feasibility of performing MRT to select and deliver personalized HIPEC
Study Overview
Brief Summary
This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
Detailed Description
Patients with peritoneal metastases from colorectal and appendix cancer are treated with cytoreductive surgery and HIPEC. However, several patients are considered unresectable due to the inability to remove all the cancer safely. Repeated (Iterative) intra-peritoneal chemotherapy delivered via HIPEC laparoscopically has been shown to have favorable outcomes with a potential increase in sensitivity to immunotherapy . Such procedures often use chemotherapy that is not tailored to the patients cancer.
In this study, patients with unresectable colorectal and appendiceal peritoneal metastases will undergo MRT on tissue biopsies to determine optimal chemotherapy regimen to be delivered intraperitoneally. For patients with unresectable disease, iterative HIPEC (IHIPEC) will be administered starting three weeks after the laparoscopy. (IHIPEC refers to HIPEC followed by systemic chemotherapy repeated 3 times with approximately 6 weeks in between each HIPEC.)
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 81 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Has histologically confirmed peritoneal metastases with primary diagnosis of AJCC 8th Edition Stage IV
- •Appendiceal adenocarcinoma (moderately/poorly differentiated, and/or signet ring cell tumors)
- •Colorectal adenocarcinoma
- •Suspected colon, small bowel, or appendiceal adenocarcinoma in setting of unknown primary
- •Limited or no extraperitoneal metastases (any of the below)
- •a) Any extraperitoneal metastases must be limited, stable and treatable
- •Has adequate organ function, as described below; all screening laboratory tests should be performed within 30 days prior to the first HIPEC
- •Expected survival at the time of first HIPEC is greater than 3 months
- •Exhibits unresectable disease (bowel or mesenteric involvement) or PCI > 19
- •Demographics
- •Adult patient at least 18 years of age at the time of signing informed consent and less than 81 years of age at the time of signing informed consent.
- •Has an ECOG performance status score of 0-
- •Male Participants
- •A male participant must agree to use contraception (barrier birth control, abstinence) during the treatment period and for at least 95 days following completion, corresponding to time needed to eliminate any study intervention(s), and refrain from donating sperm during this period.
- •Female Participants
- •A female participant of childbearing age is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception (hormonal, barrier birth control, or abstinence). Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.
- •Informed Consent
- •The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for FBR. However, the participant may participate in the main study without participating in FBR.
- •Alternative Eligibility
- •In addition to the criteria above, if a patient has undergone less than 8 rounds of chemotherapy at another institution (prior to initial diagnostic laparoscopy) and has not undergone radiation, ablative procedures, or cytoreductive surgery, then they are still eligible to enter the study at the second diagnostic laparoscopy step
Exclusion Criteria
- •Has a positive urine pregnancy test within 3 days prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Has a known allergy to medications used in this study. Note: In the event that 3 days have elapsed between the screening pregnancy test and the first dose of study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to start receiving study medication.
- •Has hypoxia as defined by pulse oximeter reading <92% at rest or requires intermittent or chronic supplemental oxygen.
- •No concurrent malignancy that may interfere with the study aims at the discretion of the investigator.
- •Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
- •Has known significant extraperitoneal metastasis.
- •Has creatine clearance <60 mL/m^2 per the Cockcroft-Gault formula
- •Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or New York Heart Association Class III or IV congestive heart failure. Medially controlled arrhythmia stable on medication is permitted.
- •Has poorly controlled hypertension defined as SBP ≥150mmHg and/or DBP ≥90mmHg.
- •Has moderate to severe hepatic impairment (Child-Pugh B or C).
- •Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
- •Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (severe dysphasia, bowel obstruction, malabsorption).
- •Has progressive disease following the first 3 months of systemic chemotherapy prior to HIPEC who is not in a stable condition to continue with the trial.
- •Prior/Concomitant Therapy
- •Has received radiation, ablative procedures, cytoreductive surgery, or systemic therapy including chemotherapy to treat metastatic disease within 3 months of initial laparoscopy.
- •Diagnostic Assessments
- •Has an active infection requiring systemic therapy.
- •Has a known active TB/ COVID infection.
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study intervention.
- •Has a known history of poorly controlled HIV infection despite anti-retroviral therapy.
- •Has a known history of HBV (defined as HBsAg reactive) or known active HCV (defined as HCV RNA [qualitative] is detected) infection that is poorly controlled.
- •Note: Testing for HBV and HCV is only required if mandated by the local health authority.
- •Other Exclusions
- •Inability to receive chemotherapy due to medical/insurance reasons.
- •Requires emergency surgery due to bleeding, perforation, or obstruction.
- •Has undergone previous iterative intraperitoneal therapy.
- •Has contraindication to chemotherapy of choice.
Arms & Interventions
MRT
Experimental
Participants with high-grade appendiceal and colorectal peritoneal metastasis will receive MRT to select and deliver personalized HIPEC regimens to participants undergoing IHIPEC
Intervention: Mass-based response testing (MRT) (Device)
Outcomes
Primary Outcomes
Feasibility of performing MRT to select and deliver personalized HIPEC
Time Frame: at end of study, up to 12 months
Feasibility is defined as the percentage of treatment naïve and pretreated patients who successfully receive drug screening results within one week of tissue sampling from at least one peritoneal biopsy. This means that the test has enough tumor cell viability and purity to come back with specific results indicating sensitivities of HIPEC drugs and does not give an inconclusive result (due to insufficient tissue sample).
Secondary Outcomes
- Concordance of MRT Results(at end of study, up to 12 months)
- One Year Overall Survival (OS)(up to 12 months)
- Percentage of participants with Perioperative and Postoperative Complications(up to 12 months)
- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) mean score(every 3 months post last IHIPEC, up to 12 months)
- Change in Comprehensive Score for Financial Toxicity (COST)(every 3 months post last IHIPEC, up to 12 months)
- Change in Peritoneal Regression Grading Score (PRGS)(at first IHIPEC post biopsy to last IHIPEC received, up to 12 months)
- Change in Peritoneal Cancer Index (PCI) Score(during each diagnostic laparoscopy at approximately month 1 and month 6)
- Complete Cytoreduction Rate(during each IHIPEC cycle, up to 12 months)
- Mean MRT Turnaround Time(up to 12 months)
- MRT Success Rate(up to 12 months)
- MRT Tumor Cell Viability(up to 12 months)
- MRT Tumor Cell Purity:(up to 12 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic TherapyNCT07277972Tianjin Medical University Cancer Institute and Hospital36
Active, not recruiting
Phase 1
一项评价 MI131 外用溶液在健康受试者中单、多次给药的安全性、耐受性和药代动力学特征的随机、双盲、安慰剂对照、剂量递增的 I 期临床试验。CTR20254865
Suspended
Phase 1
评价 PTT-501 单、多次给药的安全性、耐受性和药代动力学特征的 I 期试验CTR2025306584
Active, not recruiting
Not Applicable
在中国健康成年男性受试者中皮下注射药学变更前后 TJ101 注射液的随机、开放、单剂量、交叉设计的生物等效性试验CTR20254916120
Recruiting
Phase 2
"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer2022-501507-27-00Institut Curie, Institut Curie44